AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04302337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage adenoidectomy with transoral endoscopic ablation
Description: Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
Study NCT04302337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold curettage adenoidectomy
Description: Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
Study NCT01920750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
Study NCT01920750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab IV
Description: Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab IV
Description: Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab and Trastuzumab FDC SC
Description: The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
Study NCT04024462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
Study NCT04024462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
Study NCT04024462 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-Operative Radiotherapy
Description: If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
Study NCT01920750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mock Antigen
Description: Physiological saline
Study NCT01465568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60mg subcutaneous injection 6 monthly for 2 doses
Study NCT01465568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisphosphonates
Description: continue present bisphosphonate treatment
Study NCT00222040 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 2-MHz, low intensity transcranial ultrasound
Study NCT00222040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levovist
Description: D-Galactose and palmitic palmitique intravenous 4 g
Study NCT03604549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol UF
Description: Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
Study NCT03604549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Up to 10cc of saline will be infused via intrauterine catheter
Study NCT00600873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+) pramipexole dihydrochloride monohydrate
Description: 100 mg tid orally daily
Study NCT01307943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Description: Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
Study NCT01307943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
Study NCT00645944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
Study NCT00645944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or inactive substance (sugar pill)taken each night for all weeks of the study
Study NCT01098539 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection + sitagliptin matching placebo
Study NCT01098539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
Study NCT02040961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView Double-Lumen Tube
Description: Tracheal intubation is performed using a ETView Double-Lumen Tube
Study NCT01990807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin(IDA)
Description: 6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
Study NCT03121079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
Study NCT03501420 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
Study NCT03501420 — intervention group
Intervention type: OTHER
Intervention: PSC questionnaire
Description: All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
Study NCT03501420 — intervention group
Intervention type: OTHER
Intervention: PRFs
Description: PRFs will be completed by the physicians for seven of their consulting pSS subjects.
Study NCT04024462 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-Operative Radiotherapy
Description: If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Therapy
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Study NCT04024462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Study NCT03449108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03449108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03449108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03554616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr LLIN
Description: Dual active ingredient Long Lasting Insecticidal Net
Study NCT03554616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pyriproxyfen LLIN
Description: Dual active ingredient Long Lasting Insecticidal Net
Study NCT03554616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide LLIN
Description: Combination insecticide and synergist Long Lasting Insecticidal Net
Study NCT03019263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Nutritional counseling
Study NCT04346654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
Study NCT04346654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
Study NCT04346654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
Study NCT03923998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
Study NCT03923998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
Study NCT03554616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard LLIN
Description: Standard Long Lasting Insecticidal Net with one insecticide
Study NCT03923998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection and reconstruction
Description: Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
Study NCT03428828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala Neurofeedback
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study NCT03428828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietal Neurofeedback
Description: Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study NCT02993666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Hugger
Description: forced air warming with Bair Hugger air warmer
Study NCT01877057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturn
Study NCT00911157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Description: The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
Study NCT02381197 — intervention group
Intervention type: DEVICE
Intervention: Congo Red Dot test
Description: The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
Study NCT00911157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: unfractionated heparin (UFH)
Description: UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
Study NCT04247841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Aid
Description: The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
Study NCT04247841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scripted Risk Discussion
Description: The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
Study NCT04247841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scripted Risk Discussion
Description: The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
Study NCT01671592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine
Description: Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
Study NCT02344498 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil
Study NCT01887600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Study NCT01887600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Study NCT02137278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoactive drug therapies
Description: Continue current vasoactive therapy
Study NCT02137278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stop/reduce vasoactive drugs
Description: Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
Study NCT01407341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: musculoskeletal complications management/prevention
Description: Receive beta tricalcium-phosphate bone graft
Study NCT01407341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Receive beta tricalcium-phosphate bone graft
Study NCT01407341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01407341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03109769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Study NCT03109769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal oral hygiene instructions
Study NCT02980185 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic primary cytoreduction
Description: Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
Study NCT05210140 — intervention group
Intervention type: DRUG
Intervention: Escitalopram
Description: Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia.
Study NCT05501132 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
Study NCT05501132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
Study NCT02466126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bCBT
Description: The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health).
Study NCT01668485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic and euglycemic glucose clamp
Description: Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.